HLA-C and lung cancer: Therapies employing NK cells, which advantageously target tumor cells without MHC-dependent activation and are less likely than T cells to elicit severe side effects, are the topic of extensive research and dozens of clinical trials for both hematological and solid tumors, including lung cancer (15, 43).